Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
A whole lot of Doody
It's Howdy Doody time!
The share price has been in this range for months. As I posted a day or two ago it appears that those in control want to keep the share price below $2.20 until the Q3 merger is finalized. It seem clear that Fernandez will not play in the otc world. Once Rxmd merges with Nxpl, there is no more otc. That’s when we will see what management can accomplish.
Sometimes you gotta hop on your motorcycle and just cruise while wondering where it all went wrong.
Golf clap for Fernandez on bringing RXMD back to a sub penny pre-split valuation close. Every shareholder, including insiders; are upside down on this trade now. 👏
SEC should investigate this snake oil salesman!
Figures. Thanks Jag
My guess is a stop-loss raid.
$RXMD
Yeah that’s how I’m playing it…especially down around 1.25 I think they’re gonna play out the usually trade cycle up to the merge. It’s gotta at least spike again.
I do agree that the RXMD ticker and brand has more followers and recognition.
Progressive Care will continue to exist as a company, along with PharmCoRx, ClearMetrX, etc. But I believe that the stock ticker will be NXPL. I definitely wouldn't complain if that changed, but what is shared publicly is that we will get NXPL shares. The existing NXPL business wouldn't really fit under the name Progressive Care, IMO.
Good Luck RXMD shareholders!
Good Luck NXPL shareholders!
$RXMD + $NXPL
Check out what Generative AI reports back about Fernandez:
Generative AI is experimental
Progressive Care's CEO is Charles Fernandez, appointed in Nov 2022, has a tenure of 1.5 years. total yearly compensation is $1.66M, comprised of 5.3% salary and 94.7% bonuses, including company stock and options. directly owns 7.7% of the company's shares, worth $1.14M.
Tick Tock, Doc! ⏲ Much too long to have an investment parked without producing gains.
Six months plus the 1.5 years of Jay & Silent Fernandez killing the PPS along the way.
BTW, Charles in Charge takes a SALARY now. Remember all that "goodwill" talk he came into the company with; feeling proud of himself for not taking a paycheck from RXMD? 🤔
Exactly. We can a few more months standing on our heads. 😊
I completely agree gedi8.
I have a small buy order in NXPL but tomorrow being Friday I'll probably change that. IMHO anything under $2 is a steal. Been here over 10 years what's another 6 months? 😆
Look at the Bid/Ask spread now...26%. Absolutely crazy.
I may be way off but it seems like someone is hell bent on keeping the RXMD share price below $2.20 until the merger is complete (In Q3). RXMD will change NXPL's financial position immediately for the betteronce the merger is completed simply because RXMD has 5 times the revenues of NXPL. So when the merger is complete we will own a NASDAQ Company much stronger and larger than NXPL was before the merger and hopefully Fernandez starts to promote the "new" NXPL.
I agree with you on that, but man I've been wrong on this trade so many times I really don't know what they will do next. Lol
I think management would be throwing away a Brand Name.
I respectfully disagree sir, it should be NXPL. But since it's already trading on the NASDAQ a name change could occur.
I don't think so. RXMD will be the surviving entity of a wholly owned subsidiary of NXPL, making RXMD wholly owned by NXPL. The stock we trade will be NXPL, which already trades on NASDAQ.
Good Luck RXMD shareholders!
Good Luck NXPL shareholders!
$RXMD + $NXPL
JMO, but I think they will continue to drift down, as they have been doing. That may mean a problem for $NXPL. If they are under a dollar for 30 days they will get a non-compliance letter from NASDAQ. They'll have a lot of time to fix the issue, but for most companies it leads, eventually, to an RS. Here? Who knows.
$RXMD
Agreed, it seems like only after the merger pps could be revitalized, otherwise no movement to the year end.
Thank you all ! OK , lets wait for third quarter to finalize the merger than move to NASDAQ . As a whole we believe it should be stronger and get more attention, so its stock valuation would be much higher. Of course, we still need to talk it up to let the whole world know we are a great company and break record every quarter. In short , stop quiet and ...
Illusions of grandeur perhaps?
So why does everyone think this will rise after merger if no one uses buying either stock now … makes no sense … if it was going to run after merger you would think peoe would be scooping as many shares as possible but we cant even get over 1000 shares daily …
Apples and oranges, NexPlat takes the RXMD name and symbol.
That’s not how it works, we want NXPL to go up as we get 1.48 leverage or so on those shares.
RXMD won’t exist anymore. It will become all NXPL.
So this means we can expect the SP for both NXPL and RXMD to be flat till Q3 … no one will want to buy either stock for more than the already decided exchange rate.
That should put RXMD on the NASDAQ exchange. Finally!
Thanks Jagman. Thjat's exactly what I posted
My understanding is that merger is to be completed in Q3
From the Progressive Care announcement:
"On April 12, 2024, NextPlat Corp (NASDAQ: NXPL, NXPLW) ("NextPlat") announced a proposed business combination with Progressive Care in an all-stock transaction which is expected to provide revenue synergies and significant initial annual operating cost reductions. The transaction has been unanimously approved by the Board of Directors of both NextPlat and Progressive Care and is expected to close in the third quarter of 2024, subject to regulatory and stockholder approvals, and other customary closing conditions."
This is the second time they have stated third quarter.
$RXMD
Hopefully, the merger between the two is sooner than later. Or this could drag on until the end of the year.
After you all elites read over today report, is there any hope ? or have to wait for another year to break even ?
I thought I read in the 10k he was not taking a salary 2023. I better look at it again.
He started taking a $120K salary last year PLUS he all his stock compensation.
He’ll come out of all this just fine. We all just need to hope he brings us along for the ride
Thank you for saying this. Exactly what I was thinking but you said it perfectly!
A two second look at the balance sheet would explain
4 million more than last year, total assets up by 2 million.
If you want to know where the cash was parked go look at accounts receivable.
That transaction was to be closed April 1st, which would be included on Q2 not Q1. Futhermore, that was a NextPlat PR which I would have expected to be on NXPL books, not RXMD's Q1
Progressive Care Inc. Announces Record First Quarter 2024 Revenues of $14.6 Million, an Increase of 28% Over First Quarter 2023 Results
340B Contract Service Revenue Grows 110% as New Contract Momentum Continues MIAMI, May 15, 2024 /PRNewswire/ -- Progressive Care Inc. (OTCQB: RXMD) ("Progressive Care" or the "Company"), a personalized healthcare services and technology provider, today announced financial results for its first quarter ended March 31, 2024. The Company reported record first quarter revenues of approximately $14.6 million, a 28% increase compared to revenues reported in the first quarter of 2023. The results
Read in PR Newswire: https://stocks.apple.com/Au_PXR1OHQxWAJJ90RcpW9w
Shared from Apple Stocks
Sent from my iPhone
So another 3 or 4 years of waiting just to break even …. Great stock this turned out to be …
Not in the short term, but should in the longterm.
And will that help the price ?
Maybe purchasing outfitters.
All the while he works for free, without a salary.
Followers
|
744
|
Posters
|
|
Posts (Today)
|
0
|
Posts (Total)
|
194581
|
Created
|
01/09/11
|
Type
|
Free
|
Moderators gedi8 Truth022809 stockforce TrackDude MrMike241 |
Progressive Care Gains SEC Reporting Status
See on website
Miami, FL – April 12, 2022 – Globe Newswire via NewMediaWire – Progressive Care, Inc. (OTCQB: RXMD) (the “Company”), a personalized healthcare services and technology provider, today announced that, effective April 11, 2022, its Registration Statement on Form 10 filed with the U.S. Securities and Exchange (the “SEC”) to register its shares of common stock under Section 12(g) of the Securities Exchange Act of 1934 (the “Exchange Act”) became automatically effective.
The effective Form 10 obligates the Company to file Annual Reports on Form 10-K, Quarterly Reports on Form 10-Q and Current Reports on Form 8-K, in addition to complying with all other obligations under the Exchange Act. In addition, management and certain shareholders are subject to the beneficial ownership reporting requirements of Section 13 and 16 of the Exchange Act.
Alan Jay Weisberg, Chairman and Chief Executive Officer of the Company said, “For me, it was always important to have the Company become fully reporting with the SEC. I know how critical it is for individual and institutional investors to have the Company file its financial reports with the SEC as it provides a higher level of confidence in the information reported by the Company and a superior level of transparency. I believe that the Company’s compliance with the Exchange Act will ultimately help drive shareholder value and enable us to access higher quality institutional capital. We remain committed to strong corporate governance and steadfast in pursuit of our journey to Nasdaq.”
To view the Form 10 filling, please click:
https://www.sec.gov/Archives/edgar/data/0001402945/000149315222009357/form10-12ga.htm
Key Financial Highlights for Year Ended December 31, 2021
• Revenue at $38.9 million
- COVID-19 testing revenue of approximately $4.3 million
- ClearMetrX TPA and pharmacy dispensing revenue related to 340B earned $2.8 million on total billings of $19 million
• Gross margin increased to 26% in 2021, from 23% in 2020
• EBITDA increased to $167,000 in 2021 from $7,000 in 2020
• Cash balance of $1.4 million as of December 31, 2021
Business Highlights for the Year Ended December 31, 2021
• Re-implemented upgraded pharmacy software system
• Expanded COVID-19 business into corporate-focused services and institutional clients
• Strengthened reputation in the 340B sector by adding eight new contracts
• Filed initial S-1 registration statement
• Submitted application for uplisting to Nasdaq
Q4 2021 Reflected a Positive Bounce Back in Business
• Increase of 10% in prescription revenue to $8.9 million in the fourth quarter of 2021, from $8.1 million in the third quarter of 2021
• Increase of 8% in prescriptions filled to 114,000 in the fourth quarter of 2021, from 106,000 in the third quarter of 2021
PRODUCTS AND SERVICES
Advances in HIV/AIDS treatment has greatly increased the ability of those suffering from the disease to manage their symptoms and live longer, healthier lives. Effective management of the disease begins with taking the right medications with the right dose at the right times. For those in the HIV/AIDS community, adhering to the very strict dietary and medicinal requirements can be extremely difficult. Normal activities are often interrupted and sometimes prevented by the struggle to be in compliance.
PharmCo wants to ease this burden on those impacted by this life altering disease. We aim to make compliance with prescription regiments as easy as possible. By understanding the sensitive nature of HIV/AIDS and the needs of those afflicted, PharmCo provides the following services to patients with these special needs:
1. Confidential packaging
2. Packaging tailored to suit a patient's individual life style
3. Free delivery from a variety of sources including PharmCo's proprietary delivery fleet
4. A staff that is well trained in acute illnesses, who understands the patient's needs and
concerns
5. 24 hour emergency support
6. Timely availability of specialty medications due to our extensive inventory
7. Access to newly developed medications
PharmCo is a fully accredited DME supplier. In November 2010, as part of Medicare's competitive bidding, PharmCo was awarded a three year contract to supply hospital beds, oxygen supplies, power wheelchairs, scooters, walkers, and other related equipment and accessories in South Florida. PharmCo carries an extensive inventory of equipment and accessories with most special requests being honored with same day or next day delivery. The company offers both sales and rentals with size, color, style, and brand options available on the majority of products. Most importantly, the staff is knowledgeable, helpful and dedicated to providing superior customer service.
PharmCo offers home service and maintenance, defective product replacements, and free home installation and instruction.
PharmCo's institutional clients have come to depend on the company's proven accuracy, dispensing methods, and immediate response time. With PharmCo compliance and efficiency assistance, long term care institutions are able to provide the highest level of continued care to their patients. PharmCo provides purchasing, repackaging and dispensing of both prescription and non-prescription pharmaceutical products. PharmCo utilizes a unit-of-dose packaging system as opposed to traditional vials used for its retail customers. This method of distribution improves control and patient compliance with recommended drug therapy by increasing the timeliness and accuracy of medication dispensing. PharmCo also provides computerized maintenance of patient prescription histories, third party billing and consultant pharmacist services. Its consulting services consist primarily of evaluation of monthly patient drug therapy and monitoring the institution’s drug distribution system.
Long term care institutions can count on PharmCo for the following services:
1. On time, same day deliveries available twice a day with 24 hour emergency support
2. Language assistance in English, Spanish, French, Creole, Portuguese, Russian, and Hebrew
3. Unit-dose packaging options tailored the facility's needs
4. Prescription data accuracy
5. Extensive medication and DME inventory
6. Access to OTC medications, nutritional products and personal hygiene items
7. Provision and review of medication carts
8. Monthly pharmacy consultations- drug interactions, redundant therapies, side effects, etc.
9. Compliance updates and consultations
10. Staff Training
11. Exceptional customer service.
Toll Free: 888-919-7411 Phone: 305-919-7399 Fax: 305-919-7424
HOURS
Monday- Thursday 8:30 AM - 6:30 PM
Friday 8:30 AM - 6:00 PM
Saturday 11:00 AM - 4:00 PM
PharmCo currently services: Miami-Dade, Broward, Palm Beach, Martin, and St. Lucie Counties.
Progressive Care Reports Full Year 2021 Financial Results Highlighted by $38.9 Million in RevenueGLOBENEWSWIRE – 11:16 AM ET 03/29/2022 |
Progressive Care’s PharmcoRx Gains Status as Approved COVID-19 Test Vendor in the U.S. for Travel to Beijing Winter Olympic Games in ChinaGLOBENEWSWIRE – 7:00 AM ET 02/02/2022
|
Volume | |
Day Range: | |
Bid Price | |
Ask Price | |
Last Trade Time: |